River 3 Renal Corp

River 3 Renal Corp is a clinical-stage biotechnology company focused on the development of therapies for chronic kidney disease (CKD). Founded by RiverVest Venture Partners as part of a series of asset-centric companies, its primary asset is R3R01, a small molecule inhibitor of ketohexokinase (KHK). The company's approach targets fructose metabolism in the kidney to prevent disease progression and improve patient outcomes. In June 2024, AstraZeneca acquired River 3 Renal Corp, marking the third such acquisition from RiverVest's renal portfolio to bolster its cardiorenal pipeline. The lead candidate, R3R01, is being advanced to address the significant unmet need in patients with metabolic-driven renal impairment.